To translate this post, click on the title to open it and then click on your flag in the right menu.
A couple of years ago Wyeth introduced a new R&D protocol in drug development. It was named “Learn & Confirm” and relies most heavily on biomarkers and pharmacogenomic approaches.
As part of Learn and Confirm, Wyeth drug-development teams were encouraged to examine each compound coming through the pipeline for ways that the company can employ a biomarker-based or pharmacogenomic approach that can help move it downstream.
This R&D Methodology was based on the research developed by Lewis B. Sheiner synthesized in the paper “Clinical Pharmacology and Therapeutics” .
This methodology is naturally consistent with the unicist complexity research methodology. Therefore we working with CROs to expand this technology using the unicist healthcare cybernetic approach synthesized in the Unicist Cyberstation.
Access more information on the Unicist Approach to Complexity Research:
If you would like to receive monthly information on new scientific developments, please register here.
If you would like to get acquainted with unicist technologies, you can request an invitation as a Guest Participant in a module of Unicist Strategy.